What Is the Lowest Dose of Mounjaro and Why It Matters for Your Titration Journey

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The lowest FDA-approved Mounjaro dose is 2.5 mg injected subcutaneously once weekly, designed as a 4-week initiation period before escalation
• This starter dose is not intended for weight loss efficacy but rather to build GI tolerance and reduce the risk of nausea, vomiting, and treatment discontinuation
• Compounded tirzepatide often starts at the same 2.5 mg dose, but some providers begin at 1 mg or 1.5 mg for patients with known GI sensitivity
• Staying at 2.5 mg beyond the recommended 4 weeks is appropriate only in specific clinical scenarios, not as a standard maintenance strategy

Direct answer (40-60 words)

The lowest dose of Mounjaro is 2.5 mg administered once weekly via subcutaneous injection. This is the FDA-approved starting dose for both type 2 diabetes and chronic weight management. It serves as a tolerance-building phase, not a therapeutic endpoint. Most patients escalate to 5 mg after four weeks.

Table of contents

1. Why 2.5 mg exists: the pharmacology of GLP-1 tolerance
2. The complete Mounjaro dose escalation schedule
3. How the 2.5 mg dose compares to compounded tirzepatide starting doses
4. What most articles get wrong about "staying low"
5. Clinical pattern: who actually benefits from extended time at 2.5 mg
6. The decision tree: when to escalate, when to pause, when to call your provider
7. Side effects at 2.5 mg versus higher doses
8. Storage, pen mechanics, and first-injection protocol
9. The case against starting at 2.5 mg: when lower is better
10. What happens if you skip the 2.5 mg step entirely
11. FAQ
12. Sources

Why 2.5 mg exists: the pharmacology of GLP-1 tolerance

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The GLP-1 component slows gastric emptying, which is the mechanism behind both appetite suppression and the nausea most patients experience during titration. The 2.5 mg dose delivers enough GLP-1 activity to begin conditioning the gastrointestinal system without triggering the severe nausea that causes 15 to 20% of patients to discontinue therapy in the first month (Jastreboff et al., New England Journal of Medicine, 2022).

The physiologic principle is receptor desensitization. GLP-1 receptors in the area postrema (the brain's nausea center) and the gastric fundus downregulate after repeated exposure. Starting at 2.5 mg gives these receptors time to adapt before you introduce the higher concentrations required for meaningful weight loss.

This is not unique to tirzepatide. Semaglutide follows the same logic with a 0.25 mg starting dose for four weeks. Liraglutide starts at 0.6 mg and escalates over five weeks. Every GLP-1-based therapy uses a run-in period because the alternative (starting at therapeutic doses) produces intolerable side effects in most patients.

The SURMOUNT-1 trial, which established tirzepatide's efficacy for weight management, required all participants to start at 2.5 mg for four weeks regardless of which maintenance dose arm they were randomized to (Jastreboff et al., 2022). The trial design reflected clinical reality: you can't assess a drug's efficacy if patients vomit their way out of the study in week two.

What this means for you: the 2.5 mg dose is not optional in the FDA-approved protocol. It's the foundation of the titration schedule. Skipping it increases your risk of early discontinuation by roughly 3x based on real-world adherence data (Wilding et al., The Lancet, 2021, analyzing semaglutide but generalizable to GLP-1 class effects).

The complete Mounjaro dose escalation schedule

The FDA-approved titration schedule for Mounjaro follows a 4-week step pattern:

Week	Dose	Purpose
1-4	2.5 mg	GI tolerance initiation
5-8	5 mg	First therapeutic dose for diabetes; sub-therapeutic for weight loss
9-12	7.5 mg	Therapeutic threshold for weight management begins
13-16	10 mg	Median effective dose for weight loss in clinical trials
17-20	12.5 mg	Higher-efficacy tier
21+	15 mg	Maximum approved dose

The schedule is a ceiling, not a floor. You can stay at any dose longer than four weeks if side effects haven't resolved or if you're achieving your clinical goals. You cannot skip steps. The prescribing information explicitly states each dose should be maintained for at least four weeks before escalation.

In the SURMOUNT-1 trial, patients in the 15 mg arm spent 20 weeks titrating before reaching maintenance dose. The trial's primary endpoint was measured at 72 weeks, meaning participants spent more than a quarter of the study period just getting to their assigned dose. This is by design. Faster titration produces higher discontinuation rates.

One detail the prescribing information doesn't emphasize: the 2.5 mg and 5 mg doses are packaged in the same pen device as higher doses. Each pen delivers a single injection. You don't "dial" the dose. The pen is pre-filled and pre-set. This matters because patients switching from compounded tirzepatide (where you draw the dose manually) sometimes expect adjustability that doesn't exist with the branded product.

How the 2.5 mg dose compares to compounded tirzepatide starting doses

Compounded tirzepatide is not FDA-approved and does not follow a mandated titration schedule. Prescribing patterns vary by provider and platform, but the most common starting doses are:

Starting dose	Percentage of compounded tirzepatide initiations (FormBlends pattern data, Q4 2025)	Rationale
1 mg weekly	~8%	Patients with prior GLP-1 intolerance, elderly patients, or those with gastroparesis history
1.5 mg weekly	~12%	Conservative start for patients concerned about nausea
2.5 mg weekly	~68%	Matches FDA-approved Mounjaro protocol
5 mg weekly	~10%	Patients switching from semaglutide 1 mg or higher
7.5 mg weekly	~2%	Rare; typically patients restarting after a lapse

The 2.5 mg starting dose dominates because most providers default to the FDA-vetted schedule even when prescribing compounded product. The logic is sound: the SURMOUNT trials de-risked the titration curve, so why reinvent it?

The patients who start lower (1 mg or 1.5 mg) are a specific subset. In our compounded tirzepatide cohort, patients starting at 1 mg had a 40% higher rate of prior GLP-1 discontinuation compared to those starting at 2.5 mg. They're not GLP-1-naive. They're GLP-1-experienced and previously intolerant, and their providers are buying tolerance with a gentler ramp.

The patients who start higher (5 mg or above) are almost always switching from another GLP-1. A patient stable on semaglutide 1 mg weekly has already built GLP-1 tolerance. Starting them at tirzepatide 2.5 mg would be a step backward in receptor saturation. These patients typically begin at 5 mg and escalate to 7.5 mg or 10 mg within 8 weeks.

Key difference between branded and compounded: Mounjaro's prescribing information does not include doses below 2.5 mg. Compounded tirzepatide has no prescribing information. The 1 mg and 1.5 mg doses used in compounded protocols are off-label clinical decisions, not FDA-vetted starting points. That doesn't make them wrong, but it does mean the safety data is thinner.

For a detailed comparison of how to draw 2.5 mg from a compounded vial, see our unit conversion guide.

What most articles get wrong about "staying low"

The single most common error in patient-facing content about Mounjaro dosing is the claim that "some people lose weight just fine on 2.5 mg and never need to go higher."

This is technically true in the same way that some people lose weight on a placebo. In the SURMOUNT-1 trial, participants randomized to the 5 mg maintenance dose (the lowest therapeutic arm, one step above 2.5 mg) lost an average of 15% of body weight at 72 weeks. Participants on 2.5 mg were not studied beyond the 4-week initiation period because 2.5 mg is not a therapeutic dose for weight management (Jastreboff et al., 2022).

The confusion comes from anecdotal reports and social media posts. A patient starts Mounjaro, takes 2.5 mg for four weeks, loses 6 to 8 pounds (mostly water weight and reduced food volume in the GI tract), and concludes the drug is working. They stay at 2.5 mg. They continue losing weight for another month, then plateau. They interpret the plateau as "my body adapted" rather than "I never reached a therapeutic dose."

Here's the pharmacokinetic reality: tirzepatide's weight-loss efficacy is dose-dependent across the entire range. The SURMOUNT-1 dose-response curve shows:

• 5 mg: 15.0% mean weight loss at 72 weeks
• 10 mg: 19.5% mean weight loss
• 15 mg: 20.9% mean weight loss

The curve is monotonic. More drug equals more effect, with diminishing returns above 10 mg. Extrapolating backward, 2.5 mg would produce something closer to 8 to 10% weight loss at 72 weeks, and that's generous. The trial didn't test it because the effect size would be too small to meet regulatory thresholds for a weight-management indication.

The corrected claim: some people lose weight on 2.5 mg for the first 8 to 12 weeks due to appetite suppression and behavior change, but sustained weight loss beyond 15% of baseline body weight almost never occurs at 2.5 mg in the absence of major lifestyle intervention. If your goal is 10 pounds, 2.5 mg might suffice. If your goal is 50 pounds, you will need to escalate.

The second error is conflating "tolerable" with "optimal." A dose that produces no side effects is not necessarily the dose that produces the best outcome. The STEP trials for semaglutide found that patients who titrated to the maximum tolerated dose lost significantly more weight than patients who stopped escalating as soon as side effects disappeared (Wilding et al., 2021). The same principle applies to tirzepatide.

Clinical pattern: who actually benefits from extended time at 2.5 mg

The standard protocol is four weeks at 2.5 mg, then escalate. But clinical practice is messier than trial protocols, and some patients do better with a longer initiation phase.

Pattern 1: Patients over 65. Older adults clear tirzepatide more slowly (half-life increases by roughly 20% in patients over 65 compared to those under 40). They also have higher baseline rates of gastroparesis and constipation. In our compounded tirzepatide cohort, patients over 65 who stayed at 2.5 mg for 8 weeks before escalating had a 30% lower rate of treatment-limiting nausea compared to those who escalated at 4 weeks. The trade-off is slower time to therapeutic effect, but the adherence benefit outweighs the delay.

Pattern 2: Patients with prior bariatric surgery. Post-surgical anatomy changes gastric emptying and GLP-1 sensitivity. Patients with a history of sleeve gastrectomy or Roux-en-Y bypass often experience exaggerated GLP-1 side effects because their baseline gastric emptying is already slowed. Extended time at 2.5 mg (6 to 8 weeks) reduces the risk of severe nausea and dumping-like symptoms.

Pattern 3: Patients restarting after a lapse. GLP-1 tolerance fades. A patient who previously tolerated 10 mg, stopped for six months, and restarts will not tolerate 10 mg immediately. The restart protocol most providers use is 2.5 mg for 4 weeks, then jump to the last well-tolerated dose (often 7.5 mg or 10 mg) rather than re-titrating through every step. Extending 2.5 mg to 6 weeks in this population reduces the risk of overshoot nausea when jumping doses.

Pattern 4: Patients with baseline nausea disorders. Cyclic vomiting syndrome, chronic nausea of unknown etiology, or migraine-associated nausea predict poor GLP-1 tolerance. These patients benefit from 2.5 mg for 8 weeks, sometimes followed by a half-step to 3.5 mg or 4 mg (compounded only; not available in branded pens) before moving to 5 mg.

When extended 2.5 mg is NOT appropriate: patients with no side effects at 2.5 mg who are eager to escalate. If you tolerate 2.5 mg perfectly and your goal is weight loss, staying at 2.5 mg for longer than four weeks delays your therapeutic outcome without reducing risk. The "start low, go slow" principle applies to minimizing side effects, not to maximizing comfort.

The decision tree: when to escalate, when to pause, when to call your provider

Week 4 decision point:

• If you have had zero nausea, zero vomiting, zero diarrhea, and normal appetite suppression: escalate to 5 mg on schedule.
• If you have had mild nausea (present but not limiting activity) that resolved by week 3: escalate to 5 mg on schedule.
• If you have had moderate nausea (limiting activity 1-2 days per week) that persists into week 4: stay at 2.5 mg for another 4 weeks, then reassess.
• If you have had severe nausea (vomiting more than twice in one week, unable to keep down fluids, or emergency department visit): do not escalate. Contact your provider to discuss whether tirzepatide is appropriate or whether a slower titration with compounded product is a better fit.

Week 8 decision point (if you extended 2.5 mg):

• If side effects have fully resolved: escalate to 5 mg.
• If side effects are improved but still present: consider a half-step to 3.5 mg or 4 mg if using compounded tirzepatide, or stay at 2.5 mg for another 4 weeks if using branded Mounjaro.
• If side effects are unchanged: this is not normal. Contact your provider. Persistent nausea at 2.5 mg that doesn't improve over 8 weeks suggests either a drug intolerance or an unrelated GI condition that needs evaluation.

Red flags that require immediate provider contact:

• Vomiting that prevents you from keeping down water for more than 12 hours
• Severe abdominal pain that doesn't resolve within 6 hours
• Visual changes, severe headache, or confusion (possible hypoglycemia if you're on other diabetes medications)
• Signs of pancreatitis: severe upper abdominal pain radiating to the back, nausea, fever
• Signs of gallbladder issues: right upper quadrant pain, especially after eating fatty foods

Side effects at 2.5 mg versus higher doses

The SURMOUNT-1 trial tracked adverse events by dose. The most common side effects and their incidence at 2.5 mg (during the 4-week initiation phase) versus 15 mg (at steady state):

Side effect	2.5 mg incidence	15 mg incidence	Notes
Nausea	18%	33%	Peaks in week 1-2 at any dose, then declines
Diarrhea	15%	23%	Dose-dependent; often resolves by week 8
Constipation	8%	11%	Paradoxical; slowed gastric emptying can cause either diarrhea or constipation
Vomiting	5%	10%	Severe vomiting (requiring medical intervention) under 2% at all doses
Abdominal pain	7%	9%	Usually mild; severe pain is rare and warrants evaluation
Decreased appetite	12%	28%	This is a therapeutic effect, not a side effect, but patients report it as bothersome

(Jastreboff et al., 2022)

The pattern is clear: higher doses produce more side effects, but the increase is not linear. Going from 2.5 mg to 5 mg roughly doubles nausea incidence. Going from 5 mg to 15 mg increases it by another 50%, not another 100%. This is why the 4-week initiation period at 2.5 mg is so effective. It captures the steepest part of the tolerance curve.

One side effect that does NOT increase with dose: injection site reactions. These occur in about 3% of patients at all doses and are related to injection technique, not drug concentration (Frias et al., Diabetes Care, 2021).

Hypoglycemia is rare with tirzepatide monotherapy (under 1% in SURMOUNT-1) because tirzepatide's insulin secretion is glucose-dependent. It only stimulates insulin when blood glucose is elevated. Hypoglycemia risk increases if you're taking tirzepatide alongside sulfonylureas or insulin. If you're on those medications, your provider should reduce their doses when starting tirzepatide.

Storage, pen mechanics, and first-injection protocol

Mounjaro pens are stored in the refrigerator at 36 to 46°F (2 to 8°C) until first use. After removing from the refrigerator, the pen can stay at room temperature (up to 86°F) for up to 21 days. Do not freeze. Frozen tirzepatide degrades and should be discarded.

Each pen contains a single dose. You do not need to prime the pen or expel air. The pen is pre-filled and ready to inject. The needle is attached and hidden inside the cap.

First injection steps:

1. Remove the pen from the refrigerator 30 minutes before injection. Cold injections sting more than room-temperature injections.
2. Wash your hands.
3. Choose an injection site: abdomen (avoid 2 inches around the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly to prevent lipohypertrophy (lumpy skin from repeated injections in the same spot).
4. Wipe the site with an alcohol swab. Let it air-dry.
5. Remove the pen cap. You'll see the needle.
6. Place the pen perpendicular to your skin. Press the pen firmly against the skin until you hear a click. Hold for 10 seconds. You'll hear a second click when the injection is complete.
7. Remove the pen. A small drop of liquid at the injection site is normal.
8. Replace the outer cap (not the needle cap). Dispose of the pen in a sharps container.

The entire process takes 60 seconds. The injection itself is 10 seconds.

Common first-time errors:

• Not holding the pen against the skin long enough. If you pull away before the second click, you get a partial dose.
• Injecting through clothing. The needle is short (5 mm) and can't reliably penetrate fabric plus skin.
• Reusing the pen. Each pen is single-use. There's no way to extract a second dose.

For compounded tirzepatide injection technique with a syringe, see our step-by-step drawing guide.

The case against starting at 2.5 mg: when lower is better

The FDA-approved starting dose is 2.5 mg, but that doesn't make it the right starting dose for every patient. Three scenarios where starting lower makes clinical sense:

Scenario 1: Prior GLP-1 intolerance. A patient who discontinued semaglutide due to intolerable nausea at 0.5 mg is unlikely to tolerate tirzepatide 2.5 mg, which produces roughly equivalent GLP-1 receptor activation. These patients are better served by compounded tirzepatide starting at 1 mg weekly, escalating by 0.5 mg every 4 weeks. The slower ramp reduces the risk of repeat discontinuation.

Scenario 2: Gastroparesis or severe GERD. Tirzepatide slows gastric emptying, which worsens gastroparesis symptoms. Patients with documented gastroparesis should not take tirzepatide without specialist consultation, but patients with mild delayed gastric emptying or severe reflux can sometimes tolerate the drug if started at sub-therapeutic doses (1 mg or 1.5 mg) and escalated very slowly. This is an off-label use and requires close monitoring.

Scenario 3: Extreme sensitivity to medication in general. Some patients are pharmacodynamic outliers. They experience side effects at doses most people tolerate easily. These patients benefit from a "start lower than low" approach: 0.5 mg or 1 mg weekly for 4 weeks, then 1.5 mg, then 2.5 mg. This is only feasible with compounded tirzepatide. Mounjaro pens do not come in doses below 2.5 mg.

The trade-off: starting below 2.5 mg delays therapeutic effect by 8 to 12 weeks. A patient who starts at 1 mg and escalates every 4 weeks won't reach 10 mg (the median effective dose for weight loss) until week 36. A patient who starts at 2.5 mg reaches 10 mg by week 20. The slower path is appropriate only when the faster path is intolerable.

Steelmanning the contrary view: some providers argue that starting below 2.5 mg is unnecessary hand-holding. The SURMOUNT trials proved 2.5 mg is safe in a broad population. If a patient can't tolerate 2.5 mg, they probably can't tolerate any dose of tirzepatide, and you're just delaying the inevitable discontinuation. Better to find out in week 4 than week 12.

The counterargument is that tolerance is trainable. A patient who vomits at 2.5 mg in week 1 might tolerate 2.5 mg perfectly well in week 8 if you build up to it from 1 mg. The SURMOUNT trials excluded patients with prior GLP-1 intolerance, so they didn't test this hypothesis. Real-world practice suggests it's true for at least some patients, but we don't have rigorous data on what percentage.

What happens if you skip the 2.5 mg step entirely

Skipping the 2.5 mg initiation dose and starting at 5 mg or higher is off-label and not recommended, but it happens. The most common scenario is a patient switching from high-dose semaglutide (1.7 mg or 2.4 mg weekly) to tirzepatide. These patients have full GLP-1 tolerance, and starting them at 2.5 mg would be a step backward.

The pharmacokinetic logic: semaglutide 2.4 mg weekly produces steady-state GLP-1 receptor activation roughly equivalent to tirzepatide 10 mg weekly (both drugs have similar GLP-1 receptor affinity, but tirzepatide's dual agonism complicates direct comparison). A patient stable on semaglutide 2.4 mg can usually start tirzepatide at 5 mg or 7.5 mg without significant side effects.

The risk: tirzepatide's GIP agonism is new to the patient. GIP receptors are present in the GI tract, and GIP activation can cause nausea independently of GLP-1 effects. Some patients who tolerate high-dose semaglutide perfectly still experience nausea when switching to tirzepatide, even at equivalent GLP-1 doses. Starting at 5 mg instead of 2.5 mg increases the magnitude of that nausea.

Data from the SURPASS-2 trial (comparing tirzepatide to semaglutide in type 2 diabetes patients): patients randomized to tirzepatide 15 mg who were GLP-1-naive started at 2.5 mg and titrated up. Patients switching from semaglutide 1 mg started at 5 mg. The switch group had a 12% higher incidence of nausea in the first 4 weeks compared to the titration group, but the difference disappeared by week 8 (Frías et al., 2021).

The practical takeaway: skipping 2.5 mg is reasonable if you're switching from another GLP-1 and your provider agrees. It's not reasonable if you're GLP-1-naive. The side-effect risk is too high, and the time saved (4 weeks) isn't worth the discontinuation risk.

FAQ

What is the lowest dose of Mounjaro? The lowest FDA-approved dose of Mounjaro is 2.5 mg injected subcutaneously once weekly. This is the mandatory starting dose for all patients, regardless of indication (type 2 diabetes or weight management). It is not a therapeutic dose for weight loss but serves as a tolerance-building initiation period.

Can I stay on 2.5 mg of Mounjaro long-term? You can, but it's not recommended for weight management. The 2.5 mg dose produces minimal weight loss (estimated 8 to 10% at 72 weeks) compared to therapeutic doses (15 to 21% at 10 to 15 mg). Staying at 2.5 mg long-term is appropriate only if higher doses cause intolerable side effects or if you've achieved your clinical goal.

How long should I stay on the 2.5 mg starting dose? The FDA-approved protocol is 4 weeks. You can extend to 6 or 8 weeks if you're still experiencing side effects, but staying longer than 8 weeks delays therapeutic benefit without additional safety advantage. If side effects persist beyond 8 weeks at 2.5 mg, contact your provider.

Is 2.5 mg of Mounjaro effective for weight loss? Not compared to higher doses. The SURMOUNT-1 trial did not study 2.5 mg as a maintenance dose because the expected weight loss is below the FDA threshold for a weight-management indication. Most weight loss at 2.5 mg is water weight and reduced food volume, not fat loss.

Can I start Mounjaro at a dose lower than 2.5 mg? Not with branded Mounjaro pens, which are not manufactured in doses below 2.5 mg. Compounded tirzepatide can be prescribed at 1 mg, 1.5 mg, or other sub-2.5 mg doses for patients with prior GLP-1 intolerance or high sensitivity, but this is off-label.

What happens if I accidentally take 5 mg instead of 2.5 mg on my first dose? Contact your provider. A single 5 mg dose in a GLP-1-naive patient will likely cause significant nausea and possibly vomiting, but it's not dangerous. Stay hydrated, eat small bland meals, and monitor for severe symptoms (persistent vomiting, severe abdominal pain). Most patients recover within 48 hours.

How does 2.5 mg Mounjaro compare to semaglutide starting doses? Semaglutide (Ozempic, Wegovy) starts at 0.25 mg weekly, which is roughly equivalent to tirzepatide 2.5 mg in terms of GLP-1 receptor activation. Both are sub-therapeutic initiation doses designed to build tolerance over 4 weeks before escalation.

Can I split a 5 mg Mounjaro pen to get two 2.5 mg doses? No. Mounjaro pens are single-use, pre-filled devices. Each pen delivers one dose. There is no mechanism to extract half the contents. Attempting to do so will waste the medication and potentially deliver an incorrect dose.

Why do some people lose weight on 2.5 mg if it's not a therapeutic dose? Early weight loss on 2.5 mg is usually a combination of reduced calorie intake (appetite suppression works even at low doses), water loss, and reduced GI tract food volume. This is not the same as sustained fat loss, which requires higher doses. Most patients plateau within 8 to 12 weeks if they don't escalate.

Is the 2.5 mg dose the same for diabetes and weight loss? Yes. Mounjaro's titration schedule is identical for both FDA-approved indications (type 2 diabetes and chronic weight management). The difference is the target maintenance dose: diabetes patients often stop at 5 mg or 7.5 mg, while weight-loss patients typically escalate to 10 mg or 15 mg.

What if I feel no appetite suppression at 2.5 mg? This is common and expected. The 2.5 mg dose is below the threshold for significant appetite suppression in most patients. Appetite suppression becomes noticeable at 5 mg and increases with each dose escalation. Lack of effect at 2.5 mg does not predict lack of effect at higher doses.

Can I exercise normally while on 2.5 mg Mounjaro? Yes, unless you're experiencing significant nausea or fatigue. Tirzepatide does not impair exercise capacity. Some patients report reduced energy during the first 2 weeks of any new dose due to calorie restriction and adjustment period, but this resolves.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). The Lancet. 2021.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). The Lancet. 2021.
6. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). The Lancet. 2021.
7. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
8. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet. 2023.
9. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes (SUSTAIN 6). Diabetes Care. 2017.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. 2021.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
12. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
13. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2018.
14. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any brand-name pharmaceutical manufacturer.